Physician profile
Erin Jun
NPI 1992297170
$392.08
in general payments reported to CMS, 2019-2025
12 companies · $57.08 in 2025
The $57.08 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.20 · 2020: $34.22 · 2022: $11.82 · 2023: $149 · 2024: $83.53 · 2025: $57.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $289.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $92.90 | 2023-2025 | Myfembree |
| Myriad Women'S Health, INC. | $77.50 | 2023 | Myrisk |
| Astellas Pharma US INC | $58.84 | 2023-2025 | Veozah |
| Kyowa Kirin, INC. | $25.62 | 2019 | |
| Mayne Pharma Commercial LLC | $24.05 | 2025 | |
| Glaxosmithkline, LLC. | $19.42 | 2020 | |
| Coopersurgical, INC. | $19.17 | 2023 | Paragard T 380a |
| Genmab U.S., INC. | $17.38 | 2024 | Tivdak |
| Tesaro, INC. | $15.90 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.80 | 2020 | |
| Merck Sharp & Dohme LLC | $14.68 | 2019 | |
| Medtronic, INC. | $11.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Jun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.